Publications

Search our bibliography using the filters on the right-hand side.

Displaying 351 through 400 of 974 publications.

Maiese EM, Le Moine JG, Ainsworth C, Ahdesmaki O, Hawe E. Comparative efficacy of multiple myeloma therapies for treatment of first relapse: a systematic literature review and network meta-analysis. Poster presented at the 2017 ASCO Annual Meeting; June 5, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).

Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X, Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509

Li X, McGuinness JE, Vanegas A, Colbeth H, Vargas J, Sandoval R, Kukafka R, Crew KD. Identifying women at high-risk for breast cancer using data from the electronic health record compared with self-report. J Clin Oncol. 2017 May 30;35(15_Suppl):e13044. doi: 10.1200/JCO.2017.35.15_suppl.e13044

Muszbek N, Benedict A, Wolowacz S. Health economic modeling in oncology. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.

Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946

Telfort J, Trivedi MS, Yi HS, Colbeth H, Vanegas A, Vargas J, Sandoval R, Wood J, Dimond J, Finkelstein J, Kukafka R, Crew KD. Implementing decision support for breast cancer chemoprevention in primary care. J Clin Oncol. 2017 May;35(15 Suppl):e13038. doi: 10.1200/JCO.2017.35.15_suppl.e13038

McGuinness JE, Trivedi MS, Vanegas A, Colbeth H, Sandoval R, Kukafka R, Crew KD. Decision support for family history intake to determine eligibility for BRCA testing among multiethnic women. J Clin Oncol. 2017 May;35(15_Suppl):1586. doi: 10.1200/JCO.2017.35.15_suppl.1586

Kaye JA, Saltus CW, Calingaert B, Harris DH, Hunter S, Zong J, Brobert GP, Soriano-Gabarro M, Andrews EB. Incidence of Second Primary Malignancies (SPM) in men with Castration-Resistant Prostate Cancer (CRPC) in SEER-Medicare database. J Clin Oncol. 2017 May;2017(35):e13080.

Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.

Kurosky S, Lorenzo M, Cuyun Carter G, Parikh RC, Winfree K, Kaye JA. Health care resource utilization and costs of metastatic non-small cell lung cancer in select European countries. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A361.

Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.

Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.

Mansfield CA, Boeri M, Reyes C, Masaquel AS, Sutphin JN, Li J. How can we assess the impact of cost on patient treatment preferences in CLL treatment? Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A118.

Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.

Winnette R, Hess LM, Nicol SJ, Tai DF, Copley-Merriman C. The patient experience with soft tissue sarcoma: a systematic review of the literature. Patient. 2017 Apr;10(2):153-62. doi: 10.1007/s40271-016-0200-1

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E. Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017 Apr;58(4):809-15.

Barnett C, Auffenberg G, Cheng Z, Yang F, Wang J, Wei J, Miller D, Montie J. Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk? Poster presented at the 112th American Urological Association Annual Meeting; May 2017. Boston, MA. [abstract] J Urol. 2017 Apr; 197(4 Supplement):e552-3. doi: 10.1016/j.juro.2017.02.1311

Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017 Apr;4(2):127-35. doi: 10.4103/apjon.apjon_4_17

Lin HM, Davis KL, Kaye JA, Luptakova K, Lu G, Nagar S, Seal B. Real-world treatment patterns in relapsed or refractory multiple myeloma: evidence from a medical chart review in the United Kingdom. Poster presented at the 16th International Myeloma Workshop; March 3, 2017. New Delhi, India.

Lin HM, Davis KL, Kaye JA, Luptakova K, Gao L, Nagar S, Seal B, Mohty M. Real-world treatment patterns and health care resource utilization in relapsed or refractory multiple myeloma: evidence from a medical chart review in France. Poster presented at the 16th International Myeloma Workshop; March 3, 2017. New Delhi, India.

Mosquin PL, Rothman KJ. Reanalysis of reported associations of beryllium and lung cancer in a large occupational cohort. J Occup Environ Med. 2017 Mar;59(3):274-81. doi: 10.1097/JOM.0000000000000947

Danysh HE, Scheurer SE, Hunt RD, Venkatramani R. Malignant melanoma incidence among children and adolescents in Texas, 1995-2013. Poster presented at the American Society of Preventive Oncology 41st Annual Meeting; March 2017. Seattle, WA.

Gnanasakthy A, Hochhaus A, Giles FJ, Radich JP, Brandt P, Saglio G. ENESTfreedom trial of treatment-free remission: patient-reported quality of life before and after stopping treatment in patients with chronic myeloid leukemia in chronic phase. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S4.

Gnanasakthy A, Brandt P, Hughes TP. ENESTop trial of treatment-free remission: patient-reported quality of life before and after stopping treatment in patients with chronic myeloid leukemia in chronic phase. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27, 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S3.

Garcia-De-Albeniz XA. Effectiveness of screening colonoscopy to prevent colorectal cancer among Medicare beneficiaries aged 70 to 79 years - behind the scenes. Presented at the Winter 2017 Epidemiology Seminar Series at McGill University's Department of Epidemiology, Biostatistics and Occupational Health; February 20, 2017. Montreal, Canada. Previously presented at the 2017 Program on Biostatistics for Cancer Research at Harvard T.H. Chan School of Public Health.

Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R. Usability testing of a web-based decision aid for breast cancer risk assessment among multi-ethnic women. AMIA Annu Symp Proc. 2017 Feb 10;2016:411-20.

Ali-Shaw T, Ueng WA, Trivedi MS, Yi H, David RR, Vanegas A, Vargas JM, Sandoval R, Wood J, Kukafka R, Crew KD. Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. [abstract] Cancer Res. 2017 Feb; 77(4_Suppl). doi: 10.1158/1538-7445.SABCS16-P5-10-01

Coe AM, Trivedi MS, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. [abstract] Cancer Res. 2017 Feb; 77(4_Suppl). doi: 10.1158/1538-7445.SABCS16-P2-07-01

Brogan AP, DeMuro C, Barrett AM, D’Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017 Feb;23(2):124-34. doi: 10.18553/jmcp.2017.23.2.125.

Garcia-Albeniz X, Hsu J, Bretthauer M, Hernan MA. Effectiveness of screening colonoscopy to prevent colorectal cancer among Medicare beneficiaries aged 70-79 years: a prospective observational study. Ann Intern Med. 2017 Jan 3;166(1):18-26.

Garcia-Albeniz X. Effectiveness of screening colonoscopy to prevent colorectal cancer among Medicare beneficiaries aged 70 to 79 years - behind the scenes. Presented at the 2017 Program on Biostatistics for Cancer Research at Harvard T.H. Chan School of Public Health; 2017. Cambridge, MA.

Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, Garcia-Albeniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007

Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760

Parikh RC, Du XL, Robert MO, Lairson DR. Cost-effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients. J Manag Care Spec Pharm. 2017 Jan;23(1):64-73. doi: 10.18553/jmcp.2017.23.1.64

Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

McRoy LL, Mitra D, Hollis K, Kaye JA, Zelnak A, Cheryl J. MADELINE: a prospective observational study of mobile-app based patient reported outcomes in advanced breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

Mansfield C, Masaquel A, Sutphin J, Weiss ES, Gutierrez ME, Wilson J, Li J, Reyes C. What do patients prioritize in selecting chronic lymphocytic leukemia (CLL) treatments? Presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):1239. doi: 10.1182/blood.V128.22.1239.1239

Lin HM, Davis KL, Kaye JA, Luptakova K, Gao L, Nagar S, Seal B, Mohty M. Real-world clinical outcomes by cytogenetic risk category in relapsed or refractory multiple myeloma: evidence from a cohort review in France. Poster presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):4784. doi: 10.1182/blood.V128.22.4784.4784

Barnett C, Denton BT. Developing near-optimal biomarker-based prostate cancer screening strategies. Presented at the 2016 INFORMS Annual Meeting; November 14, 2016. Nashville, TN.

Barnett C, Merdan S. Data analytics for optimal detection of metastatic prostate cancer. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.

Andrews EB, Gilsenan A, Midkiff K, Harris D. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma - Editorial. Ann Epidemiol. 2016 Nov;26(11):751-3. doi: 10.1016/j.annepidem.2016.08.011

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Boye ME, Houghton K, Stull DE. Rethinking what missing patient-reported outcome (PRO) data can teach us about outcomes and survival in oncology clinical trials. Presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria.

Lorenzo M, Hess L, Nicol S, Parikh R, Candrilli SD, Kaye JA. Advanced soft-tissue sarcoma-related treatment patterns and outcomes in elderly patients in the United States. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Mansfield C, Srinivas S, Chen C, Hauber AB, Hariharan S, Matczak E, Sandin R. The effect of information on preferences for treatments of metastatic renal cell carcinoma. Curr Med Res Opin. 2016 Nov;32(11):1827-38. doi: 10.1080/03007995.2016.1211521

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’Yachkova Y, Nagar S, Candrilli SD, Kaye JA. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A751.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’Yachkova Y, Nagar SP, Candrilli SD, Kaye JA. Real-world treatment patterns and survival for patients with advanced soft tissue sarcoma receiving systemic therapy in Spain. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’Yachkova Y, Nagar SP, Candrilli SD, Kaye JA. Advanced soft tissue sarcoma: systemic treatment patterns and survival in France. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Purser M, Mladsi DM, Kaye JA. Cost-effectiveness of sonidegib versus vismodegib for the treatment of patients with locally advanced basal cell carcinoma not amenable to surgery or radiotherapy. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A731.